Recent Headlines
Within Biotechnology
NuvOx Announces Publication of Research Article in Cancer Research Communication
NuvOx Pharma announced publication of a research article, “Dodecafluoropentane Emulsion as a Radiosensitizer in Glioblastoma Multiforme” in Cancer Research Communications. https://aacrjournals.org/cancerrescommun/article/3/8/1607/728499. Evan Unger, MD, President and CEO of NuvOx,... - September 01, 2023 - NuvOx Therapeutics
Huntington Study Group Welcomes FDA Approval of New Drug for Chorea in Huntington’s Disease
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in clinical trials for Huntington’s disease (HD), today shares that the Phase 3 pivotal KINECT®-HD study conducted by HSG in collaboration with Neurocrine Biosciences,... - August 18, 2023 - Huntington Study Group
Huntington Study Group Announces Positive Topline Results for Virtual Unified Huntington’s Disease Rating Scale® (vUHDRS®) Study
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), today announces positive topline results from its Virtual Unified Huntington’s Disease Rating Scale®... - August 14, 2023 - Huntington Study Group
The FOXG1 Research Foundation Appoints Dr. Soo-Kyung Lee as Chief Scientific Officer to Lead Therapeutics for FOXG1 Syndrome, an Autism-related Rare Disease
The FOXG1 Research Foundation (FRF), a parent-led rare disease patient organization focused on driving therapeutics for FOXG1 syndrome, an Autism-related neurological condition, announced today the appointment of Dr. Soo-Kyung Lee as the new Chief Scientific Officer of the FOXG1 Research Foundation (FRF). Dr. Lee’s dedication to curing FOXG1 syndrome is deeply personal as a mother to Yuna, diagnosed with FOXG1 syndrome in 2009. - August 12, 2023 - FOXG1 Research Foundation
Minus K Technology Announces Announces Its Eighth U.S. Educational Giveaway of Vibration Isolators to Colleges and Universities
Minus K Technology, over the past 30 years has worked with businesses, universities and laboratories all over the world, supplying negative-stiffness vibration isolation products for research within universities, aerospace, audio reproduction, crystal growth, neuroscience, biology, chemistry,... - August 09, 2023 - Minus K Technology Inc.
Creative Diagnostics Announces New Reagents for Bioanalysis of Antibody Drug Conjugates
Creative Diagnostics has announced a series of new reagent solutions to assist researchers in the bioanalysis of ADCs. - August 06, 2023 - Creative Diagnostics
Creative Diagnostics Announces New Antimicrobial Susceptibility Testing Services
Creative Diagnostics announced the launch of its new Antimicrobial Susceptibility Testing (AST) services. - August 06, 2023 - Creative Diagnostics
The ALS Therapy Development Institute and Unite Genomics Partner to Integrate Electronic Health Records Into the ALS Research Collaborative
The ALS Therapy Development Institute (ALS TDI) is partnering with Unite Genomics, a leading healthcare data analytics company, to integrate electronic health record (EHR) data into the ALS Research Collaborative (ARC) via Unite Genomics’ state-of-the-art healthcare data access and analytics... - August 02, 2023 - ALS Therapy Development Institute
Huntington Study Group and CHDI Foundation Collaborate on Enroll-HD
HSG Clinical Research, Inc. - the Huntington Study Group’s clinical research organization (CRO) and wholly owned subsidiary (collectively referred to here as HSG) - has begun providing CRO services for CHDI Foundation’s Enroll-HD observational study and clinical research platform in the... - July 25, 2023 - Huntington Study Group
Cayman and Navinci Announce Strategic Partnership, Expanding Access to Next-Generation Tools for Spatial Proteomics
Cayman and Navinci have partnered to bring next-generation proximity ligation-based solutions for spatial proteomics to US and Canada-based researchers. - July 13, 2023 - Cayman Chemical Company
Paras Biopharma (Biologics CDMO) Announces Industry Leading Scale-up Development & Production Process of an “Onco-Immunology Fc-fusion Biologic”
Paras Biopharma (Biologics CDMO) Finland team is pleased to announce that its extensive efforts have resulted in the successful scale-up, optimization & development of a biologically-active onco-immunology, “peptide FC-fusion” biologic. - July 12, 2023 - Paras Biopharmaceuticals Finland Oy
Creative Diagnostics Introduces qPCR Assay for Rapid Virus Detection and Quantification
Creative Diagnostics has introduced its new qPCR Assay to the research community. - July 07, 2023 - Creative Diagnostics
Creative Diagnostics Launches New Reagent Solutions for Herpesvirus Research
Creative Diagnostics has announced the launch of new reagent solutions for herpesvirus research. - July 07, 2023 - Creative Diagnostics
Paras Biopharma (Biologics CDMO) Maximises Recombinant Protein Expression in Microbial Systems – To Facilitate Economical Scale-Up in Production of Biologics
Paras Biopharma (Biologics CDMO) Finland, a leading biopharmaceutical technology development company in the Nordic region, maximises recombinant protein expression in Microbial Systems in its fully-equipped biologics production facility in Finland. - July 04, 2023 - Paras Biopharmaceuticals Finland Oy
PharmStars Announces Spring 2023 Accelerator Graduates: 13 Digital Health Startups Complete PharmStars’ Pharma-Focused Accelerator Program
PharmStars, the pharma-focused accelerator for digital health startups, announces that 13 startups have graduated from its Spring 2023 program focused on “Innovations in Women’s Health or Health Equity.” The graduating startups successfully completed PharmaU, PharmStars’ 10-week program. PharmaU culminated with a Showcase Event, held in Boston in May, that brought together the participating startups and PharmStars’ innovation-minded pharma members. - June 20, 2023 - PharmStars
International LabAutomation Day is June 21
Celebrating Lab Automation; Laboratory automation refers to the use of technology, equipment, and software to streamline and optimize laboratory processes and operations. It involves automating repetitive tasks, data collection and analysis, sample handling, and other activities in a laboratory setting. By leveraging various automated systems, laboratories can enhance efficiency, accuracy, reproducibility, and throughput while reducing human error and the time required to perform experiments. - June 20, 2023 - Laboratory Robotics Interest Group (LRIG)
ALPCO Receives FDA 510(k) Clearance for the Calprotectin Immunoturbidimetric Assay
American Laboratory Products Company, Ltd. ("ALPCO"), a global provider of specialty diagnostic solutions, today announced recent FDA 510(k) clearance of its Calprotectin Immunoturbidimetric Assay. The Calprotectin Immunoturbidimetric (IT) Assay is now IVDD and 510(k)-cleared for in... - June 15, 2023 - ALPCO
NuvOx Announces Glioblastoma Patient Treatment for Phase IIb RESTORE Trial
NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, announced that it enrolled and treated the first subject in the Phase IIb RESTORE Trial for newly-diagnosed glioblastoma multiforme... - June 09, 2023 - NuvOx Therapeutics
Creative Diagnostics Announces the Launch of Radial Immunodiffusion Testing Service
Creative Diagnostics has launched its new Single Radial Immunodiffusion Testing services for the biological industry. - June 09, 2023 - Creative Diagnostics
Creative Diagnostics Launches Highly Specific Antibodies Against FXIIIa/F13A1 for Vascular Diseases
Creative Diagnostics has launched a set of highly specific antibodies against FXIIIa/F13A1 for vascular diseases. - June 09, 2023 - Creative Diagnostics
PharmStars Announces “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface” Theme for its Fall 2023 Accelerator
PharmStars, the pharma-focused accelerator for digital health startups, is accepting applications for its Fall 2023 cohort around the theme “Digital Innovations in Therapeutic Delivery: Supply Chain to the Patient Interface.” The cohort is open to startups with digital health solutions that pharma can use to innovate therapeutic supply chain management, medication delivery, or the patient-drug experience for small molecules, biologics, or advanced therapies. Applications are due July 10, 2023. - June 06, 2023 - PharmStars
New Research Benchmarks Biopharmaceutical Perceptions of Global CRO Thought Leadership
Landmark Research Analyzes Perspectives of US and EU Biopharma C-Suite, Clinical Operations and Medical/Regulatory Affairs Professionals on Global CRO Thought Leadership. - June 01, 2023 - Life Science Strategy Group, LLC
Huntington Study Group Announces Call for Abstracts for 30th Annual Meeting
The Huntington Study Group (HSG), with a mission of accelerating treatments that make a difference for those impacted by Huntington’s disease, together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease... - June 01, 2023 - Huntington Study Group
Creative Diagnostics Announces Calprotectin Reagents for Inflammatory Disease Research
Creative Diagnostics, a leading global supplier of raw materials, antibodies, and reagents to the biotechnology industry, is proud to announce the launch of its new line of Calprotectin Reagents for the study of inflammation disease. Calprotectin is an abundant inflammatory marker in the... - May 20, 2023 - Creative Diagnostics
Creative Diagnostics Introduces Viral Replicon Assay Service to Support Virology Research
Creative Diagnostics recently introduced a series of Viral Replicon Assay services to assist researchers in identifying and studying viruses. - May 20, 2023 - Creative Diagnostics
The Inc. Magazine, USA Includes Paras Biopharma (Biologics CDMO) as One of the Top 10 Most Innovative Biotech Companies to Follow in 2023
Paras Biopharma (Biologics CDMO), a biopharmaceutical technology development company is pleased to be included by The Inc. Magazine, USA as “One of the Top 10 Most Innovative Biotech Companies to Follow in 2023.” The Inc. Magazine serves as an online "go-to" informative tool for business leaders and entrepreneurs, including CEOs and owners of small-to-midsize companies to success, providing news, advice, and inspirational articles. - May 19, 2023 - Paras Biopharmaceuticals Finland Oy
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine
Neurocrine Biosciences Announces Publication of Full KINECT™-HD Phase 3 Study Results of Valbenazine for the Treatment of Chorea Associated with Huntington’s Disease in The Lancet Neurology. - Statistically Significant Improvement in Chorea Associated with Huntington’s Disease... - May 19, 2023 - Huntington Study Group
PharmStars Announces Spring 2023 Startup Showcase Event Underway
PharmStars, the pharma-focused accelerator for digital health startups, announces that its fourth Showcase Event begins May 16, 2023. The Showcase is the culmination of the Spring 2023 10-week accelerator program. At the Showcase, each startup in the fourth cohort makes a formal presentation to and meets individually with PharmStars’ pharma members. The theme of the Spring 2023 program is digital innovations in women’s health or health equity. - May 16, 2023 - PharmStars
Huntington Study Group Achieves Last Patient Last Visit for Its Observational Study to Test Virtual Use of the Unified Huntington’s Disease Rating Scale®
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., announces an important milestone in the novel observational study Virtual Unified Huntington’s Disease Rating Scale (vUHDRS™). The last participant completed the last visit, marking... - May 16, 2023 - Huntington Study Group
Parvus Therapeutics Announces a Publication Describing the Cellular Origin of Treg Cells Generated Endogenously by Navacim Therapy
Parvus Therapeutics announced today the publication of data showing that peptide-MHC class II-coated nanoparticles (Navacims) operate by triggering the expansion of cognate T follicular helper (TFH) cells. - May 09, 2023 - Parvus Therapeutics U.S., Inc.
Cyclists Ride Through MA, NH, and ME in Tri-State Trek to Benefit ALS Research
June 24-25, cyclists of all levels are invited to participate in the Tri-State Trek, a New England cycling event raising funds for cutting-edge research to end ALS. - May 03, 2023 - ALS Therapy Development Institute
New Traceable Opioid Material® Kit Expands Coverage to Other Emerging Drugs of Concern in Seized Samples and Toxicological Casework
Cayman Chemical and the Centers for Disease Control and Prevention (CDC) have released a new addition to the Traceable Opioid Material® Kits (TOM Kits®) product line that expands testing laboratory capabilities beyond synthetic opioids to include additional emerging drugs of abuse that are commonly found as co-drugs in fentanyl-containing samples. - April 30, 2023 - Cayman Chemical Company
Creative Diagnostics Introduces New Low Endotoxin Antibodies for Researchers
Creative Diagnostics recently introduced a new line of low endotoxin antibodies to biopharmaceutical research laboratories. - April 29, 2023 - Creative Diagnostics
Creative Diagnostics Introduces Virus Yield Reduction Assay Service
Creative Diagnostics introduced the Virus Yield Reduction Assay Service to support researchers in evaluating the antiviral activity of compounds. - April 29, 2023 - Creative Diagnostics
Fight ALS Film Fest Aims to Continue the Momentum to Beat ALS
The second annual Festival will explore universal themes of life-changing diseases through examination of ALS. - April 26, 2023 - ALS Therapy Development Institute
Brain Tumor Investment Fund Names Managing Director
National Brain Tumor Society’s venture philanthropy affiliate appoints industry veteran to lead fund designed to invest in and accelerate development of promising new technologies for patients with brain cancer. - April 26, 2023 - National Brain Tumor Society
NuvOx Receives SPAN Grant
NuvOx Receives SPAN Grant to Conduct Late-stage Preclinical Studies of Putative Neuroprotectants Combined with Reperfusion - April 24, 2023 - NuvOx Therapeutics
Thermo Fisher Partners with ALPCO-GeneProof to Broaden Their CE-IVD Molecular Assay Portfolio
ALPCO-GeneProof, a global leader in diagnostics, and Thermo Fisher announced a strategic partnership that brings the TaqPath Menu | GeneProof PCR kits to market. The partnership combines the strengths of ALPCO-GeneProof’s expertise in molecular diagnostics with Thermo Fisher’s robust... - April 17, 2023 - ALPCO
DistillerSR Appoints New Board Members to Accelerate Scaleup and Healthcare Analytics Domain Expertise
DistillerSR® Inc., the market leader in AI-enabled literature review automation software and creator of DistillerSR™, today welcomed Dr. Khaled El Emam and Jason Flick as new board members. The two serial entrepreneurs join Andrew Pinkerton, Partner at Thomvest Ventures, Maria Pacella,... - April 11, 2023 - DistillerSR
HSG and HD-CAB Collaborate to Provide Global Patient Advisory Board
The Huntington Study Group (HSG) together with its wholly owned subsidiary, HSG Clinical Research, Inc., a world leader in conducting clinical trials for Huntington’s disease (HD), recently collaborated with Huntington’s Disease – Community Advisory Board (HD-CAB) to provide a... - March 30, 2023 - Huntington Study Group
New Research on Decentralized Clinical Trial (DCT) Strategies to Boost Patient Diversity
Current and Future Clinical Trial Participants Link Enhanced Diversity and Inclusion of Underrepresented Patient Populations to DCT - March 29, 2023 - Life Science Strategy Group, LLC
World Class Hospitals Join DNA Damage Response Consortium to Bring Forward New Treatments for Adults and Children with Brain Cancer
Researchers from St. Jude Children’s Research Hospital, NYU, UCSF, and the University of Minnesota join National Brain Tumor Society and Yale-led Initiative - March 29, 2023 - National Brain Tumor Society
HSG Announces 30th Annual Meeting
The Huntington Study Group (HSG), a world leader in conducting clinical trials and providing educational programming for Huntington’s disease (HD), recently announced that their 2023 Annual Meeting will be held November 2-4, 2023 at the Sheraton Grand at Wild Horse Pass in Chandler, AZ, a... - March 21, 2023 - Huntington Study Group
Gallant Deepens Its Bench by Adding Dr. Valentine Williams as Senior Vice President of Clinical Development and Regulatory
Furthering its mission to bring regenerative medicine to all pets, animal biotech company Gallant Therapeutics welcomes an industry leader, Dr. Val Williams, to its pioneering team. - March 17, 2023 - Gallant
Breaking Barriers: ALS TDI Unveils Groundbreaking ALS Research Collaborative (ARC) to Accelerate Global Research in ALS
The ALS Research Collaborative will revolutionize ALS research by providing scientists with unprecedented access to the data and tools they need to discover new treatments and accelerate progress toward cures for ALS. - March 15, 2023 - ALS Therapy Development Institute
New Research Identifies Latest Clinical Development and CRO Outsourcing Trends in China
Groundbreaking Research Explores the Chinese Innovative Biopharmaceutical Clinical Development Market, CRO Outsourcing and Future Growth with Over 100 Chinese Biopharma Professionals - March 15, 2023 - Life Science Strategy Group, LLC
Creative Diagnostics Introduces Microneutralization Assay Service for Virus Detection
Creative Diagnostics recently introduced the Microneutralization Assay Service to support research labs in detecting virus-specific neutralizing antibodies from human and animal sera. - March 12, 2023 - Creative Diagnostics
Creative Diagnostics Introduces ELISA Kit Development Services to Support IVD Research
Creative Diagnostics recently introduced comprehensive contract ELISA kit development services to the R&D and IVD communities. - March 12, 2023 - Creative Diagnostics
NuvOx Newly Issued US Patent
NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role, announced that it has been issued US Patent No. 11,571,467, “Dodecafluoropentane emulsion (DDFPe) as a stroke and ischemia... - March 02, 2023 - NuvOx Therapeutics
Creative Diagnostics Introduces TCID50 Assay Service for Determining Viral Titers
Creative Diagnostics recently introduced the TCID50 Assay Service suitable for drug sensitivity tests, infectious units quantification, the determination of virus doses, as well as virus release studies. - February 17, 2023 - Creative Diagnostics